Multiple sclerosis (MS) is considered an immune disease of the central nervous system, and the most important effective therapies are based on drugs which are able to modify the systemic immune system (immunomodulating and immunosuppressant agents)
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial
D’Amico, EmanueleConceptualization
;
2017-01-01
Abstract
Multiple sclerosis (MS) is considered an immune disease of the central nervous system, and the most important effective therapies are based on drugs which are able to modify the systemic immune system (immunomodulating and immunosuppressant agents)File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Exp. Rev. Prec. Med. Drug Devel. 2017.pdf
solo gestori archivio
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
588.54 kB
Formato
Adobe PDF
|
588.54 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
